263 related articles for article (PubMed ID: 20484029)
1. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling.
Feldmann G; Mishra A; Hong SM; Bisht S; Strock CJ; Ball DW; Goggins M; Maitra A; Nelkin BD
Cancer Res; 2010 Jun; 70(11):4460-9. PubMed ID: 20484029
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras.
Eggers JP; Grandgenett PM; Collisson EC; Lewallen ME; Tremayne J; Singh PK; Swanson BJ; Andersen JM; Caffrey TC; High RR; Ouellette M; Hollingsworth MA
Clin Cancer Res; 2011 Oct; 17(19):6140-50. PubMed ID: 21825040
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-139 inhibits pancreatic-cancer carcinogenesis by suppressing RalB via the Ral/RAC/PI3K pathway.
Wang Y; Zheng Y; Chen Q; Dai Y; Li T
Arch Biochem Biophys; 2021 Jun; 704():108719. PubMed ID: 33290747
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase 5 mediates pleiotrophin-induced endothelial cell migration.
Lampropoulou E; Logoviti I; Koutsioumpa M; Hatziapostolou M; Polytarchou C; Skandalis SS; Hellman U; Fousteris M; Nikolaropoulos S; Choleva E; Lamprou M; Skoura A; Megalooikonomou V; Papadimitriou E
Sci Rep; 2018 Apr; 8(1):5893. PubMed ID: 29651006
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.
Feldmann G; Mishra A; Bisht S; Karikari C; Garrido-Laguna I; Rasheed Z; Ottenhof NA; Dadon T; Alvarez H; Fendrich V; Rajeshkumar NV; Matsui W; Brossart P; Hidalgo M; Bannerji R; Maitra A; Nelkin BD
Cancer Biol Ther; 2011 Oct; 12(7):598-609. PubMed ID: 21768779
[TBL] [Abstract][Full Text] [Related]
6. Activation of the Ral and phosphatidylinositol 3' kinase signaling pathways by the ras-related protein TC21.
Rosário M; Paterson HF; Marshall CJ
Mol Cell Biol; 2001 Jun; 21(11):3750-62. PubMed ID: 11340168
[TBL] [Abstract][Full Text] [Related]
7. Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation.
Tecleab A; Zhang X; Sebti SM
J Biol Chem; 2014 Nov; 289(45):31296-309. PubMed ID: 25210032
[TBL] [Abstract][Full Text] [Related]
8. Aberrant overexpression of the Rgl2 Ral small GTPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through Ral-dependent and Ral-independent mechanisms.
Vigil D; Martin TD; Williams F; Yeh JJ; Campbell SL; Der CJ
J Biol Chem; 2010 Nov; 285(45):34729-40. PubMed ID: 20801877
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
Gysin S; Lee SH; Dean NM; McMahon M
Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
[TBL] [Abstract][Full Text] [Related]
10. Targeting the cyclin-dependent kinase 5 in metastatic melanoma.
Sharma S; Zhang T; Michowski W; Rebecca VW; Xiao M; Ferretti R; Suski JM; Bronson RT; Paulo JA; Frederick D; Fassl A; Boland GM; Geng Y; Lees JA; Medema RH; Herlyn M; Gygi SP; Sicinski P
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8001-8012. PubMed ID: 32193336
[TBL] [Abstract][Full Text] [Related]
11. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
[TBL] [Abstract][Full Text] [Related]
12. Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.
Hu C; Dadon T; Chenna V; Yabuuchi S; Bannerji R; Booher R; Strack P; Azad N; Nelkin BD; Maitra A
Mol Cancer Ther; 2015 Jul; 14(7):1532-9. PubMed ID: 25931518
[TBL] [Abstract][Full Text] [Related]
13. Involvement of Ras and Ral in chemotactic migration of skeletal myoblasts.
Suzuki J; Yamazaki Y; Li G; Kaziro Y; Koide H
Mol Cell Biol; 2000 Jul; 20(13):4658-65. PubMed ID: 10848592
[TBL] [Abstract][Full Text] [Related]
14. Ras-related small GTPases RalA and RalB regulate cellular survival after ionizing radiation.
Kidd AR; Snider JL; Martin TD; Graboski SF; Der CJ; Cox AD
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):205-12. PubMed ID: 20619549
[TBL] [Abstract][Full Text] [Related]
15. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
16. Discovery and characterization of small molecules that target the GTPase Ral.
Yan C; Liu D; Li L; Wempe MF; Guin S; Khanna M; Meier J; Hoffman B; Owens C; Wysoczynski CL; Nitz MD; Knabe WE; Ahmed M; Brautigan DL; Paschal BM; Schwartz MA; Jones DN; Ross D; Meroueh SO; Theodorescu D
Nature; 2014 Nov; 515(7527):443-7. PubMed ID: 25219851
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase 5 regulates endothelial cell migration and angiogenesis.
Liebl J; Weitensteiner SB; Vereb G; Takács L; Fürst R; Vollmar AM; Zahler S
J Biol Chem; 2010 Nov; 285(46):35932-43. PubMed ID: 20826806
[TBL] [Abstract][Full Text] [Related]
18. Ras inhibitors display an anti-metastatic effect by downregulation of lysyl oxidase through inhibition of the Ras-PI3K-Akt-HIF-1α pathway.
Yoshikawa Y; Takano O; Kato I; Takahashi Y; Shima F; Kataoka T
Cancer Lett; 2017 Dec; 410():82-91. PubMed ID: 28951129
[TBL] [Abstract][Full Text] [Related]
19. CDK5 positively regulates Notch1 signaling in pancreatic cancer cells by phosphorylation.
Chu Q; Wang L; Zhang J; Wang W; Wang Y
Cancer Med; 2021 Jun; 10(11):3689-3699. PubMed ID: 33960694
[TBL] [Abstract][Full Text] [Related]
20. Differential involvement of RalA and RalB in colorectal cancer.
Martin TD; Der CJ
Small GTPases; 2012; 3(2):126-30. PubMed ID: 22790202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
